12 rats
|
IV Vehicle (n=4)
5 ul IV siEGFP (20ng; n=4)
5 ul IV siRhoA (10ng; n=4)
5 ul IV siEGFP (15ng; n=4)
5 ul IV siRhoA (20ng; n=4)
5 ul IV siRhoA (30ng; n=4)
5 ul IV siRhoA (40ng; n=4)
|
RT–PCR (to assess knockdown efficiency and the activation of innate immunity)
|
3 Rats
|
Intact control eyes (n=3)
|
IHC (contractility & fibrosis)
|
4 Rats
|
3.5 ul IC of 5ng/µl TGFβ1 (n=4)
|
7d IHC (contractility & fibrosis)
|
3.5 ul IC 3.5ul PBS (n=4)
|
7d IHC (contractility & fibrosis)
|
4 Rats
|
3.5 ul IC 5ng/µl TGFβ1 (n=4)
|
35d IHC (contractility & fibrosis)
|
3.5 ul IC PBS (n=4)
|
35d IOP; IHC (contractility & fibrosis)
|
6 Rats
|
3.5 ul IC 5ng/µl TGFβ1+5ng/µl siRhoA (n=6)
|
7d IOP; IHC (contractility & fibrosis)
|
IC 5 ng/µl TGFβ1+5ng/µl siEGFP (n=6)
|
7d IOP; IHC (contractility & fibrosis)
|
| 6 Rats |
IC 5 ng/µl TGFβ1+5ng/µl siRhoA (n=6)
|
35d IOP; IHC (contractility & fibrosis)
|
| IC 5 ng/µl TGFβ1+5ng/µl siEGFP (n=6) |
35d IOP; IHC (contractility & fibrosis) |
